Literature DB >> 26600222

Current and Evolving Treatments of Genotype 1 Hepatitis C Virus.

Saleh Alqahtani1, Mark Sulkowski2.   

Abstract

Development of antiviral agents that target the hepatitis C virus (HCV) has improved the success and tolerability of treatment, especially for patients with HCV genotype 1 infection. The new treatment options mean that clinicians are better able to prevent complications from chronic HCV infection. The field of direct-acting antiviral therapies for HCV infection continues to advance at a rapid pace, and many more potential treatment regimens are being investigated. This article presents a summary of the current treatments available for patients infected with HCV genotype 1 and looks ahead to those that may play a role in the future.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Hepatitis; Hepatitis C; Ledipasvir antiviral; Simeprevir; Sofosbuvir

Mesh:

Substances:

Year:  2015        PMID: 26600222     DOI: 10.1016/j.gtc.2015.06.001

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  6 in total

1.  Unreported alcohol use was common but did not impact hepatitis C cure in HIV-infected persons who use drugs.

Authors:  Risha Irvin; Geetanjali Chander; Kathleen M Ward; Sean Manogue; Oluwaseun Falade-Nwulia; Juhi Moon; Catherine G Sutcliffe; Sherilyn Brinkley; Taryn Haselhuhn; Stephanie Katz; Kayla Herne; Lilian Arteaga; David L Thomas; Shruti H Mehta; Mark S Sulkowski
Journal:  J Viral Hepat       Date:  2020-01-07       Impact factor: 3.728

2.  Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals.

Authors:  Albert Do; Denise A Esserman; Supriya Krishnan; Joseph K Lim; Tamar H Taddei; Ronald G Hauser; Janet P Tate; Vincent Lo Re; Amy C Justice
Journal:  J Gen Intern Med       Date:  2020-04-27       Impact factor: 5.128

3.  The Prevalence of Hepatitis C Virus Core Amino Acid 70 Substitution and Genotypes of Polymorphisms Near the IFNL3 Gene in Iranian Patients With Chronic Hepatitis C.

Authors:  Danesh Kadjbaf; Maryam Keshvari; Seyed Moayed Alavian; Ali Pouryasin; Bita Behnava; Shima Salimi; Leila Mehrnoush; Pegah Karimi Elizee; Heidar Sharafi
Journal:  Hepat Mon       Date:  2016-05-03       Impact factor: 0.660

Review 4.  Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection.

Authors:  Vinay Sundaram; Kris V Kowdley
Journal:  Hepat Med       Date:  2016-06-28

5.  Sharing the cure: Building primary care and public health infrastructure to improve the hepatitis C care continuum in Maryland.

Authors:  Risha Irvin; Boatemaa Ntiri-Reid; Mary Kleinman; Tracy Agee; Jeffrey Hitt; Onyeka Anaedozie; Tolu Arowolo; Hope Cassidy-Stewart; CaSaundra Bush; Lucy E Wilson; Alexander J Millman; Noele P Nelson; Lauren Canary; Sherilyn Brinkley; Juhi Moon; Oluwaseun Falade-Nwulia; Mark S Sulkowski; David L Thomas; Michael T Melia
Journal:  J Viral Hepat       Date:  2020-08-05       Impact factor: 3.517

6.  Comparison of hepatitis C virus testing recommendations in high-income countries.

Authors:  Risha Irvin; Kathleen Ward; Tracy Agee; Noele P Nelson; Claudia Vellozzi; David L Thomas; Alexander J Millman
Journal:  World J Hepatol       Date:  2018-10-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.